Literature DB >> 28042790

Testicular and paratesticular tumors in children.

Francisco Javier Murcia-Pascual1, Raquel Gracia-Rodríguez1, Fernando Vázquez-Rueda2, Pedro López Pereira3, Rosa María Paredes Esteban1.   

Abstract

OBJECTIVES: Testicular (TT) and paratesticular (PT) tumors account for 1-2%of all infant solid tumors. Due to the increased frequency of benign tumors, conservative management is recommended. Our experience and the therapeutic approach adopted considering testis-sparing surgery, was reviewed.
METHODS: A retrospective observational study concerning testicular and paratesticular tumors in our hospital between 1998 and 2016, was performed. Age, side, symptoms, imaging, treatment methods, histological findings and evolution were reviewed.
RESULTS: Nineteen cases of TT and PT were reviewed in 17 patients. A painless scrotal mass was found in most cases as the initial presentation (79%). Tumor markers were normal in all cases. Similar distribution between germ cell and stromal testicular tumors was found Nevertheless, benign and malignant PT proportion was similar. Testis preserving surgery was performed in 58% of TT and in 57% of PT.
CONCLUSIONS: Due to the high incidence of the benign histological findings, testicular sparing surgery should be considered as a first therapeutic option, especially in those cases with normal tumor markers.

Entities:  

Mesh:

Year:  2016        PMID: 28042790

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  2 in total

Review 1.  [Testicular tumors in prepubertal boys-organ preservation possible more often than expected].

Authors:  R Stein; M Dürken; K Zahn; Nina Younsi
Journal:  Urologe A       Date:  2020-03       Impact factor: 0.639

2.  Testis-sparing surgery for testicular tumors in children: a 20 year single center experience and systematic review of the literature.

Authors:  Juan I Bois; Roberto L Vagni; Francisco I de Badiola; Juan M Moldes; Paul D Losty; Pablo A Lobos
Journal:  Pediatr Surg Int       Date:  2021-01-17       Impact factor: 1.827

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.